



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

VOSORITIDE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VOSORITIDE	VOXZOGO	47677		GPI-10 (3095008000)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of achondroplasia and meet **ALL** of the following criteria?
 - The patient is 5 years of age or older
 - The patient has open epiphyses

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 vial per day.**
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **VOSORITIDE (Voxzogo)** requires the following rule(s) be met for approval:

- A. You have achondroplasia (a type of bone condition)
- B. You are 5 years of age or older
- C. You have open epiphyses (the end part of a long bone)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Voxzogo.

REFERENCES

- Voxzogo [Prescribing Information]. Novato, CA: BioMarin Pharmaceutical, Inc.; November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/22

Created: 01/22

Client Approval: 02/22

P&T Approval: 01/22